Document is current
Any future updates will be listed below
-
Authors
van Opijnen, Mark P.
Broekman, Marike L. D.
de Vos, Filip Y. F. https://orcid.org/0000-0002-9082-5991
Cuppen, Edwin
van der Hoeven, Jacobus J. M.
van Linde, Myra E.
Compter, Annette
Beerepoot, Laurens V.
van den Bent, Martin J.
Vos, Maaike J.
Fiebrich, Helle-Brit
Koekkoek, Johan A. F.
Hoeben, Ann
Kho, Kuan H.
Driessen, Chantal M. L.
Jeltema, Hanne-Rinck
Robe, Pierre A. J. T.
Maas, Sybren L. N.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05186064 at ClinicalTrials.govDocuments that mention this clinical trial
Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study
https://doi.org/10.1186/s12920-022-01343-4
-
Funding
Funding for this research was provided by:
Oncode Insitute (P2020-0029)
- License Information
-
More Information
Article History
Received: 18 February 2022
Accepted: 30 August 2022
First Online: 4 November 2022
Declarations
:
: The study has been approved by the Medical Ethical Committee of Leiden/The Hague/Delft, and by the other participating medical sites, namely Amsterdam University Medical Centers, University Medical Center Utrecht, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Elisabeth-Tweesteden Hospital, Erasmus Medical Center, Isala Clinics, University Hospital Maastricht, Medisch Spectrum Twente, Radboud University Medical Center and University Medical Center Groningen. All patients will be asked for written informed consent before they can participate in this study.
: Not applicable.
: JJMvdH and EC are employed by Hartwig Medical Foundation.
